The Enterprise Value as of July 2024 (TTM) for Reata Pharmaceuticals, Inc. (RETA) is 6.68B

According to Reata Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 6.68B. This represents a change of 161.45% compared to the average of 2.56B of the last 4 quarters.

Reata Pharmaceuticals, Inc. (RETA) Historical Enterprise Value (quarterly & annually)

How has RETA Enterprise Value performed in the past?

The mean historical Enterprise Value of Reata Pharmaceuticals, Inc. over the last ten years is 1.31B. The current 6.68B Enterprise Value has changed 50.77% with respect to the historical average. Over the past ten years (40 quarters), RETA's Enterprise Value was at its highest in in the December 2019 quarter at 5.96B. The Enterprise Value was at its lowest in in the December 2014 quarter at -15873000.00.

Reata Pharmaceuticals, Inc. (RETA) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Reata Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Reata Pharmaceuticals, Inc. (RETA) Average Enterprise Value

How has RETA Enterprise Value performed in the past?

The current Enterprise Value of Reata Pharmaceuticals, Inc. (RETA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Reata Pharmaceuticals, Inc. (RETA) Enterprise Value vs. Peers

How is RETA’s Enterprise Value compared to its peers?

Reata Pharmaceuticals, Inc.’s Enterprise Value is less than Sarepta Therapeutics, Inc. (14.59B), greater than Mirati Therapeutics, Inc. (3.91B), greater than Krystal Biotech, Inc. (5.75B), greater than Intercept Pharmaceuticals, Inc. (915.81M), less than PTC Therapeutics, Inc. (0), greater than Madrigal Pharmaceuticals, Inc. (2.49B), greater than CureVac N.V. (5.56B), greater than Vir Biotechnology, Inc. (508.99M), greater than Propanc Biopharma, Inc. (1.40B), greater than Viking Therapeutics, Inc. (1.06M), less than Terns Pharmaceuticals, Inc. (7.23B), greater than Akero Therapeutics, Inc. (518.07M), greater than null (1.36B),

Build a custom stock screener for Reata Pharmaceuticals, Inc. (RETA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Reata Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Reata Pharmaceuticals, Inc. (RETA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Reata Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.